Results 211 to 220 of about 120,942 (241)
Some of the next articles are maybe not open access.
Neurology, 2002
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +3 more sources
Although all dopaminergic drugs are effective in reducing tremor, no single drug has been shown to be clearly superior in the treatment of tremor. Levodopa produces a mean improvement of 30 to 50% in the Unified Parkinson's Disease Rating Scale (UPDRS) subtest for rest tremor. Comparable improvement is achieved with the dopamine agonists.
openaire +3 more sources
Dopamine agonists in Parkinson's disease
Neurology, 1995The main pathologic hallmark of Parkinson's disease is a degeneration of the dopaminergic cells in the substantia nigra, pars compacta and--to a lesser extent--in the ventral tegmental area. Striatal dopamine concentrations are significantly reduced before clinical symptoms become apparent.
Gerrit Tissingh +3 more
openaire +3 more sources
Expert Opinion on Pharmacotherapy, 2002
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +3 more sources
(2002). Synthetic dopamine agonists. Expert Opinion on Pharmacotherapy: Vol. 3, No. 4, pp. 363-364.
openaire +3 more sources
Dopamine agonists in schizophrenia: a review
European Neuropsychopharmacology, 1995Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology.
Otto Benkert +2 more
openaire +2 more sources
Alopecia induced by dopamine agonists [PDF]
Neurology, 2002 We report two women with PD who developed alopecia while being treated with the dopamine agonists pramipexole and ropinirole. The alopecia reversed partially after the drugs were discontinued. Both women were postmenopausal and had no history of hair loss or other dermatologic disorders.
Rowena E. Tabamo, Alessandro Di Rocco
openaire +2 more sources
Switching and combining of dopamine agonists [PDF]
Journal of Neurology, 2004 Dopamine agonists have been proved safe and effective as initial therapy in early stages of Parkinson's disease. Prospective long-term clinical trials demonstrated that initial symptomatic treatment with a dopamine agonist is associated with a significantly reduced risk for motor complications in comparison with levodopa therapy.
Theresa Glöckler +2 more
openaire +2 more sources
Dopamine and dopamine receptor agonists in cardiovascular therapy
Critical Care Medicine, 1990Dopamine (DA)--previously regarded simply as the precursor of norepinephrine--is now known to have its own unique effects on cardiovascular regulation which are mediated, in part, by activating specific DA receptors. DA has long been used in the treatment of shock and heart failure.
Michael B. Murphy, William J. Elliott
openaire +3 more sources
Dopamine agonists in Parkinson’s disease
Expert Review of Neurotherapeutics, 2008Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications.
Mitsutoshi Yamamoto +1 more
openaire +3 more sources
Switching and combining dopamine agonists
Journal of Neural Transmission, 2003Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.
B. Herting +3 more
openaire +3 more sources
Ropinirole hydrochloride, a dopamine agonist
Acta Crystallographica Section C Crystal Structure Communications, 2006Ropinirole hydrochloride, or diethyl[2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl]ammonium chloride, C16H25N2O+.Cl-, belongs to a class of new non-ergoline dopamine agonists which bind specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4).
Krishnan Ravikumar +1 more
openaire +3 more sources